Search results
Results From The WOW.Com Content Network
Dual-energy X-ray absorptiometry (DXA, or DEXA [1]) is a means of measuring bone mineral density (BMD) with spectral imaging. Two X-ray beams, with different energy levels, are aimed at the patient's bones. When soft tissue absorption is subtracted, the bone mineral density (BMD) can be determined from the absorption of each beam by bone. Dual ...
A scanner used to measure bone density using dual energy X-ray absorptiometry. Bone density, or bone mineral density, is the amount of bone mineral in bone tissue.The concept is of mass of mineral per volume of bone (relating to density in the physics sense), although clinically it is measured by proxy according to optical density per square centimetre of bone surface upon imaging. [1]
DXA scanners can be used to diagnose osteopenia or osteoporosis as well as to measure bone density over time as people age or undergo medical treatment or lifestyle changes. [23] Information from the DXA scanner creates a bone mineral density T-score by comparing a patient's density to the bone density of a healthy young person.
bone density studies for osteoporosis assessment Dual X-ray absorptiometry and laser technique (DXL) in the area of bone density studies for osteoporosis assessment is an improvement to the DXA Technique , adding an exact laser measurement of the thickness of the region scanned.
Primary, or involuntary osteoporosis, can further be classified into Type I or Type II. [1] Type I refers to postmenopausal osteoporosis and is caused by the deficiency of estrogen. [1] While senile osteoporosis is categorized as an involuntary, Type II, and primary osteoporosis, which affects both men and women over the age of 70 years.
It is an official journal of the International Osteoporosis Foundation and the National Osteoporosis Foundation. [3] The journal is published monthly and includes original research on all areas of osteoporosis and its related fields, alongside reviews, educational articles, and case reports. The co-editors-in-chief are J.A. Kanis and F. Cosman.
In 2018, HHS released an update to the first set of guidelines. This 2018 edition provides guidelines for people aged three years and older and summarizes the new knowledge gained from studies that were conducted since the first edition was released in 2008. These Guidelines can be tailored to meet individual interests, lifestyles, and goals.
Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.